Online inquiry

IVTScrip™ mRNA-Anti-SEMA4D, VX-15(Cap 1, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ15750MR)

This product GTTS-WQ15750MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets SEMA4D gene. The antibody can be applied in Multiple sclerosis (MS) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Chimeric; Humanized
RefSeq NM_001142287.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 10507
UniProt ID Q92854
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-SEMA4D, VX-15(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ15750MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11874MR IVTScrip™ mRNA-Anti-GUCY2C, MLN-0264(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MLN-0264
GTTS-WQ3610MR IVTScrip™ mRNA-Anti-LYPD3, BAY 1129980(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BAY 1129980
GTTS-WQ362MR IVTScrip™ mRNA-Anti-ALB&IL6R, 20A11-9mer-ALB11(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA 20A11-9mer-ALB11
GTTS-WQ15872MR IVTScrip™ mRNA-Anti-CD19, XmAb5871(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA XmAb5871
GTTS-WQ607MR IVTScrip™ mRNA-Anti-RTN4, 6A3-IgG4(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA 6A3-IgG4
GTTS-WQ6429MR IVTScrip™ mRNA-Anti-HA, CT-P22(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CT-P22
GTTS-WQ10952MR IVTScrip™ mRNA-Anti-HAVCR2, MBG-453(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA MBG-453
GTTS-WQ5421MR IVTScrip™ mRNA-Anti-CD74, CD74-DOX (ADC)(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CD74-DOX (ADC)
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW